Dr. Grossman’s Blog

In the first study, Jennifer S.L. Tan, MBBS, BE at the University of Sydney, Australia and her colleagues evaluated data from 2,454 participants in the Blue Mountains Eye Study of men and women aged 49 and older. Those who consumed one serving of fish per week were shown to have a 31 percent lower adjusted risk of developing early AMD compared with those who consumed less.

In the second article, Elaine W. T. Chong, MD, PhD, of the Centre for Eye Research Australia and her associates evaluated data from 6,734 men and women aged 58 to 69 who participated in the Melbourne Collaborative Cohort Study. Dietary questionnaires completed between 1990 and 1994 were analyzed for the intake of various foods and individual fatty acids. Follow up examinations conducted between 2003 and 2006 detected 2,872 cases of early age-related macular degeneration and 88 cases of late disease.

A high intake of trans-unsaturated fats was associated with a significant increase in late macular degeneration, with those whose intake was categorized as among the top 25 percent of participants having a 76 percent greater risk than those whose intake was among the lowest fourth.

Olive oil emerged as protective against late disease. When those who reported consuming at least 100 milliliters per week olive oil were compared with those who consumed less than 1 milliliter per week, they were found to have a 52 percent lower risk of late AMD.

For early AMD, those whose omega-3 fatty acid intake was among the top 25 percent had a 15 percent lower risk compared with those whose intake was among the lowest quarter.

For more information on nutrition and macular degeneration and related research studies, see NaturalEyeCare’s Section on Macular Degeneration.

A team of scientists and surgeons from the Institute of Ophthalmology at University College London and the Moorfields Eye Hospital in London has developed a stem cell therapy to treat age-related macular degeneration (AMD), the most common cause of vision loss in the elderly.
“Under the new treatment, embryonic stem cells are transformed into replicas of the missing cells,” writes The Times of London. “They are then placed on an artificial membrane which is inserted in the back of the retina.”

Pharmaceutical giant Pfizer announced this week that it will fund the development of the therapy; UCL professor Pete Coffey, who led the research team, predicts the therapy will be available as part of a simple, one-hour procedure within six or seven years.The researchers are applying for approval to conduct a clinical trial on humans; it would be just the second-ever trial conducted on humans using embryonic stem cells. Laboratory trials completed by the British team have demonstrated that stem cells can prevent blindness in rats with a similar disease to AMD. They have also successfully tested elements of the technology in pigs.

For natural approaches to help prevent the onset of macular degeneration as well as help preserve vision for those with macular degeneration, visit the Natural Eye Care web site

A small study by Japanese researchers demonstrates an increased blood supply to the retina upon stimulation of certain acupuncture points. Needles were inserted near the posterior base of the thumbs of volunteers while investigators used a laser to scan the retinal blood flow. Both volume and velocity increased in these patients. The work was done at the ophthalmology department at Kyoto Prefectural University of Medicine.

Reported by Dr. Kazuhiko Mori at the annual meeting of the Association for Vision and Ophthalmology in Fort Lauderdale this past May.

For more related information on natural eye care, go to www.naturaleyecare.com

Scientists through the US Department of Energy are testing artificial retinas that they hope can restore partial sight to people who’ve lost their vision to the most common causes of blindness.

The Sylmar, Calif., company produced the devices for the U.S. Energy Department’s Artificial Retina Project. The department has been engaged in biological research since the atomic bomb tests of the 1950s raised fears of radiation poisoning.

The current version is being tested on 17 blind people in the U.S. and Europe, and more patients are being enrolled. At a retina conference in October, patients reported improvements in orientation and mobility. They were able to find a door from 20 feet away and to follow a line on the floor for 20 feet, Mech reported.

Meanwhile, researchers in the Energy Department’s National Laboratories are creating a third-generation artificial retina. Much smaller than its predecessors, the device will contain 200 or more electrodes on a thin, flexible film that curves to fit the shape of the retina. Human tests are scheduled to begin in 2011.

For more information, go to http://artificialretina.energy.gov/index.shtml

For more information and specific research studies by eye condition on nutrition and vision, go to Natural Eye Care

Lutein and zeaxanthin have been well researched as being essential nutrients in both helping to prevent the onset of macular degeneration as well as helping protect vision for those with macular degeneration. People with macular degeneration have been shown to have reduced macular pigment optical density (MPOD).

Meso-zeaxanthin is the third major carotenoid found in macular pigment (along with lutein and zeaxanthin).

A new study showed that supplementation of gelcaps containing mostly mesozeaxanthin (along with some lutein and zeaxanthin) resulted in increased blood serum levels of all three carotenoids during the 120 day study supplementation period, and was effective in increasing macular pigment optical density (MPOD).

Ref: Florida International University (Nutr Metab. 2007;4:12) (DOI:10.1186/1743-7075-4-12).

For more information on related studies, go to www.naturaleyecare.com

The findings provide hope for treating blindness caused by optic-nerve damage, but
also look promising for spurring similar regeneration in the spinal cord and brain.
Researchers said Monday a newly discovered growth factor could hold the key to regenerating damaged optic nerves — and more. The research team at Children’s Hospital in Boston say they have found a naturally occurring, previously unrecognized growth factor that stimulates regeneration in injured optic nerves.
The findings provide hope for treating blindness caused by optic-nerve damage, but
also look promising for spurring similar regeneration in the spinal cord and brain,
they said.

The growth factor is called oncomodulin and when it was added to retinal nerve cells
in the lab, with known growth-promoting factors already present, the growth of axons
– or cells in the optic nerves — nearly doubled.

No other growth factor was as potent, the researchers said.

More Nerve Regeneration

In live rats with optic-nerve injury, oncomodulin released from tiny sustained-release
capsules increased nerve regeneration five- to seven-fold when given along with
a drug that helps cells respond to oncomodulin, the team said.

Oncomodulin also appears to switch on a variety of genes associated with axon growth,
the researchers said.

“Out of the blue, we found a molecule that causes more nerve regeneration than
anything else ever studied,” said one of the study investigators. We expect
this to spur further research into what else oncomodulin is doing in the nervous
system and elsewhere.

The data are published in the May 14 online edition of Nature Neuroscience.

For more related research, go to www.naturaleyecare.com (see “Research” section).

Results from the vision component of the Women’s Antioxidant and Folic Acid Cardiovascular Study, also known as WACS, were presented at the ARVO 2007 Annual Meeting. Researchers from the Brigham and Women’s Hospital and the National Eye Institute concluded that the data from this randomized trial indicate that supplementation with folic acid, vitamins B6 and B12 reduced the risk of AMD in women with cardiovascular disease (CVD) (1).

These three B-vitamins, particularly folic acid, have been shown to reduce high levels of the naturally occurring compound, homocysteine. Research has implicated elevated plasma levels of homocysteine in the development of vascular diseases including choroidal neovascularization in exudative AMD.

Study Design and Methods: A total of 8,171 female health professionals, 40 years or older with pre-existing CVD or having at least three risk factors for the disease were enrolled in the trial. The women were randomized to receive vitamin C (500 mg daily), vitamin E (600 IU every other day), beta-carotene (50 mg every other day) or placebo in the WACS secondary prevention trial.

Of this group, 5,422 women were subsequently randomized to also receive a placebo or folic acid (2.5 mg), vitamin B6 (50 mg) and vitamin B12 (1 mg) daily. Of these women, 5,205 did not have a diagnosis of AMD, and were included in this analysis. There were two primary outcome measures: a) confirmed AMD (self reported and supported by medical record evidence of an AMD diagnosis after randomization) and b) confirmed AMD with vision loss – defined as vision to 20/30 or worse which was attributable to this condition.

Results: A total of 137 cases of AMD were documented, including 69 cases of AMD with vision loss, during an average of 7.3 years of treatment and follow-up. Fifty-five cases occurred in the treatment group, while the placebo group had 82 documented cases. Relative risk was 0.66 (95% confidence interval, p = 0.02). For AMD with vision loss, there were 26 cases in the B-vitamin group compared to 43 among placebo takers. Relative risk was 0.60 (95% confidence interval, p = 0.04). In summary, women taking supplemental B vitamins were 34% less likely to develop AMD and 40% less likely to have AMD-related vision loss than women in the control group.

Note: While very high doses of the 3 B vitamins were tested in this group of women with CVD, lower doses may well have been effective. For example, a placebo-controlled, randomized dose response study in people with a history of CVD found that the decrease in homocysteine was proportionate to the folate dose up to – and not beyond – 800 mcg daily (2). This dose achieved an average 23% drop in plasma homocysteine compared to placebo – a drop of about the same magnitude found in trials using up to 5,000 mcg folate daily (3). Additionally, excessive amounts of folic acid have recently been implicated in colorectal tumor growth (4,5).

References :
Christen WG, et al. Folic acid plus B-vitamins and age-related macular degeneration in a randomized trial in women. Invest Ophthalmol Vis Sci 48:E-abstract 1152, ARVO, 2007.
Wald DS, et al. Randomized trial of folic acid supplementation and serum homocysteine levels. Arch of Internal Med 161:695-700, 2001.
Homocysteine Lowering Trialists’ Collaborative. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. BMJ 316:894-8, 1998.
Mason JB, et al. A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: A hypothesis. Cancer Epidemiol Biomarkers Prev 16:1325-9, 2007.
Cole BF, et al. Folic acid for the prevention of colorectal adenomas. JAMA 297:2351-9, 2007.
Cook NR, et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: Results from the WAC Study. Arch of Int Med 167:1610-18, 2007.